PIFELTRO® (doravirine) is an innovative medication developed by Merck & Co., specifically designed for the treatment of HIV-1 infection in adults. Here we will explore its formulation, uses, advantages, side effects, dosage, precautionary measures, and more, providing a thorough overview of this important therapeutic option.
Formulation of PIFELTRO® (doravirine)
PIFELTRO® is a prescription medication designed to treat HIV-1 infection in adults as part of a combination antiretroviral regimen. It is formulated for oral administration and contains doravirine as the active ingredient.
Active Ingredient
- Doravirine (100 mg): Each tablet contains 100 mg of doravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the activity of the HIV-1 reverse transcriptase enzyme. This prevents the virus from multiplying and helps reduce the amount of HIV in the body.
Inactive Ingredients
The tablet also includes inactive components that support the stability, absorption, and palatability of the medication. These may include:
- Lactose monohydrate
- Microcrystalline cellulose
- Croscarmellose sodium
- Magnesium stearate
- Povidone
- Sodium stearyl fumarate
These ingredients are carefully chosen to ensure the medication’s efficacy, bioavailability, and ease of production.
Uses of PIFELTRO® (doravirine)
PIFELTRO® is primarily used as part of a complete HIV treatment regimen. It can be prescribed for:
- Treatment-Naive Patients: Those who have never received HIV treatment before.
- Switching Therapy: Patients who are currently on an effective antiretroviral therapy but may benefit from switching to a regimen that includes doravirine.
Advantages of PIFELTRO® (doravirine)
- Convenience: Once-daily dosing helps improve adherence to the treatment regimen.
- Efficacy: Clinical trials have shown that doravirine is effective in suppressing viral loads in patients.
- Favorable Side Effect Profile: Compared to older antiretrovirals, doravirine may have fewer side effects, particularly in terms of metabolic effects.
Side Effects of PIFELTRO® (doravirine)
PIFELTRO® (doravirine) is an antiretroviral medication used in combination with other medications to treat HIV-1 infection in adults. While it is generally well-tolerated, some individuals may experience side effects. It’s essential to discuss potential risks and benefits with your healthcare provider.
Common Side Effects
- Nausea
- Fatigue
- Headache
- Diarrhea
- Rash
Less Common but Possible Side Effects
- Dizziness: Some individuals report feeling lightheaded or dizzy after taking PIFELTRO®.
- Abdominal Pain: Stomach discomfort or cramps may occur.
- Vomiting: In rare cases, nausea can lead to vomiting.
- Sleep Disturbances: Insomnia or trouble sleeping has been reported by some patients.
- Mood Changes: Feelings of depression or anxiety may occur.
Dosage of PIFELTRO® (doravirine)
The standard dosage of PIFELTRO® is one tablet (100 mg) taken once daily, with or without food. It’s crucial to follow the healthcare provider’s instructions for the best outcomes. For patients who have missed a dose, it should be taken as soon as remembered, but if it’s close to the next dose, the missed dose should be skipped.
Precautionary Measures of PIFELTRO® (doravirine)
Before starting PIFELTRO®, patients should:
- Inform their healthcare provider of any allergies, current medications, and medical history.
- Be aware of potential drug interactions, particularly with other antiretrovirals or medications that affect liver enzymes.
- Undergo regular monitoring for viral load and overall health during treatment.
Year of Invention of PIFELTRO® (doravirine)
PIFELTRO® was approved by the FDA in August 2018, marking a significant advancement in HIV treatment options available to patients.
Company Information of PIFELTRO® (doravirine)
PIFELTRO® is produced by Merck & Co., a global healthcare company known for its commitment to research and innovation in pharmaceuticals. Merck has a long history of developing treatments for infectious diseases, including HIV, and continues to be a leader in this field.
Price in USA and UK of PIFELTRO® (doravirine)
The price of PIFELTRO® can vary based on location, insurance coverage, and pharmacy. In the United States, the average retail price for a 30-day supply (30 tablets) is approximately $4,500, though costs can be significantly lower with insurance or patient assistance programs. In the UK, prices can vary, but the NHS typically negotiates costs that can significantly reduce the price for patients.
Conclusion
PIFELTRO® (doravirine) represents a significant advancement in the management of HIV-1 infection. With its convenient dosing, effective viral suppression, and a favorable side effect profile, it offers a valuable option for many patients. However, as with any medication, it’s essential for patients to work closely with their healthcare providers to ensure the best outcomes and to remain informed about potential side effects and interactions.
